Firebrick Pharma Limited announced the appointment of Dr. Richard Treagus as a non-executive director on the Firebrick board of directors, with effect from 1 June 2022. Dr. Treagus was previously Commercial Director for Aspen Pharmacare in South Africa, responsible for sales and marketing of pharmacy and consumer products. More recently, from 2006 to 2012, he was CEO of Acrux Limited, which grew 10-fold in value during his tenure and from 2013 to 2020, he was Executive Chairman of Neuren Pharmaceuticals Limited, which grew 6-fold in value during his tenure.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.049 AUD | -2.00% |
|
-7.55% | -2.00% |
Jun. 13 | Firebrick Pharma Launches Nasodine Nasal Spray in Singapore | MT |
May. 23 | Firebrick Pharma Obtains Nasodine Composition Patent in South Africa | MT |
1st Jan change | Capi. | |
---|---|---|
-2.00% | 6.72M | |
+60.25% | 846B | |
+38.56% | 628B | |
-4.49% | 360B | |
+18.30% | 322B | |
+9.64% | 297B | |
+14.15% | 240B | |
+3.11% | 224B | |
+16.98% | 223B | |
+12.87% | 173B |
- Stock Market
- Equities
- FRE Stock
- News Firebrick Pharma Limited
- Firebrick Appoints Richard Treagus as Director